Interviews

Dr. Julie Atay discusses her poster at ACC 2011 on "Cost Analysis of Substituting Dabigatran for Warfarin in an Anticoagulant Management Program."

Dr. Poulin discusses his poster which is a cost analysis of 300 patients from Quebec, Canada, in an atrial fibrillation and congestive heart failure trial.

Dr. Alexander Goehler explains that due to an increase in longevity of HIV-infected patients, cardiovascular issues are becoming more prevalent.

Dr. David Blumenthal, The National Coordinator for HIT under President Barack Obama, opens the floor to the Healthcare Innovations at the National Press Club

Dr. Sachin Jain, Office of the National Coordinator for HIT, opens the floor to the Healthcare Innovations and HIT Q&A Session at the National Press Club.

Dr. William Shrank, Harvard Medical School, Brigham and Women's Hospital, discusses his paper and answers questions at the National Press Club in Washington, DC.

Geoff Gerhardt, MPP, House Ways and Means Committee, discusses his paper at the National Press Club

Dr. Amol Navathe, US Dept of Health and Human Services

Katlyn Nemani, BA, Tufts University School of Medicine, discusses her paper

Dr. Deneen Vojta, UnitedHealthcare, discusses her paper and answers questions at the Healthcare Innovations and HIT Q&A Session at the National Press Club.

Dr. Aaron McKethan, US Dept of Health and Human Services, discusses his paper and answers questions at the National Press Club.

Dr. Melinda Beeuwkes Buntin, US Dept of Health and Human Services, discusses her papers and answers questions.

The Q&A Session from the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.

Dr. Sachin Jain, closes the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.

Dr. A Mark Fendrick welcomes the participants to the Healthcare Innovations and HIT Q&A Session at the National Press Club.

Dr. A. Mark Fendrick explains the concept of Value-Based Insurance Design (VBID) and how it works.

Suzette Kox, MPharm, Secretary General of the International Generic and Biosimilar Medicines Association (IGBA), discusses challenges faced jointly by the US and EU biosimilars markets.

Gillian Woollett, MA, DPhil, senior vice president, Avalere Health, discusses how confirming "sufficient likeness" in biosimilar development can and should replace the current "totality of the evidence” approach to biosimilar development.